Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

VABYSMO is indicated for the treatment of adult patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).

.
Vial Prescribing Information
Pre-Filled Syringe Prescribing Information
Real-world impact revealed: Insights from UK Ophthalmologists using VABYSMO in their clinical practice

Uncover the impact of VABYSMO in UK clinical practice, from treatment outcomes to consequences for medical retina services.

 

Can real-world insights from these UK clinics be applied to your own clinical practice? Click each video to find out!
Seema Arora on real-world findings from Hull University Teaching Hospital

Uncover real-world data showcasing the efficacy, tolerability, and treatment intervals with VABYSMO in treatment-naïve nAMD patients, as Consultant Ophthalmologist Ms Seema Arora provides insights into patient and service outcomes. Click below to hear her insights firsthand.
Niro Narendran on VABYSMO’s impact at the Royal Wolverhampton NHS Trust

Discover how switching to VABYSMO can impact visual and anatomical outcomes, as well as treatment burden on services and patients. Consultant Ophthalmologist Ms Niro Narendran discusses real-world data, including service impact, for previously treated patients with nAMD. Click below to uncover the impact.

 
Radhika Krishnan on VABYSMO outcomes at University Hospital Southampton

Learn about the real-world impact of VABYSMO on patients with treatment-naïve DMO and related service outcomes, as Consultant Ophthalmologist Ms Radhika Krishnan offers clinical insights. Click below to share in her learnings.

 

These are the opinions of clinicians selected by Roche UK. The clinicians received funding for this activity from Roche UK. 

These promotional videos have been funded and developed by Roche Products Ltd. Please note this video contains data for Roche products and the prescribing information can be found at the top of this page.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
 
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
 
Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.